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http:WHAT THIS PAPER ADDS
This study investigates, by means of a discrete choice experiment, the factors that inﬂuence endovascular
treatment decisions by specialists for patients with descending thoracic aortic aneurysm (dTAA). The results
show that specialists’ preferences vary widely and demonstrate clinical uncertainty, especially in octogenarians,
with a reluctance to offer thoracic endovascular aneurysm repair to women. Aneurysm diameter dominates
treatment preferences, but patient ﬁtness and length of aortic coverage (>25 cm) are also inﬂuential, although
the landing zone distal to left subclavian artery is not. This study highlights the need for new evidence con-
cerning the treatment of dTAA.Objective: To investigate and rank factors that inﬂuence endovascular treatment decisions by specialists for
patients with descending thoracic aortic aneurysm (dTAA).
Methods: Specialists completed a diagrammatic survey describing uncertainty about the beneﬁt of thoracic
endovascular aneurysm repair (TEVAR) for dTAA with respect to age, sex, and aneurysm diameter. Subsequently,
a detailed discrete choice experiment was designed. Specialists were recruited and asked to indicate treatment
their preference (TEVAR or surveillance) in 25 hypothetical cases of dTAA, with variable patient attributes: age,
sex, American Society of Anesthesiologists (ASA) grade, aneurysm diameter, adequate landing zone distal to left
subclavian artery (LSA), and length of aortic coverage. Data were analysed using multiple logistic regression.
Results: The diagrammatic survey, based on 50 respondents, showed that uncertainty about the beneﬁts of
TEVAR was greatest for patients aged 80e85 years (up to 47% of respondents were “unsure”) and that
uncertainty increased with increasing aneurysm diameter (for an 80-year-old man, 7% were unsure at 5.5 cm and
33% were unsure at 7.0 cm). Seventy-one specialists (mainly from Europe and North America, 86% vascular
surgeons and 98% working in units offering TEVAR) completed the discrete choice experiment. Preference for
TEVAR increased greatly with enlarging diameter: adjusted odds ratios (OR) >5.5e6.0 cm ¼ 15.8 (95%
conﬁdence interval [CI] 9.83e25.40); >6.0e6.5 cm ¼ 393.0 (95% CI 202.00e766.00); >6.5e7.0 cm ¼ 1829.0
(95% CI 400.00e4,181.00). TEVAR was less likely to be preferred in patients older than 75 years (>75e80 years
OR 0.32, 95% CI 0.21e0.49; >80e85 years ¼ 0.18, 95% CI 0.11e0.28); in women (OR 0.52, 95% CI 0.37e0.74); in
patients classiﬁed as ASA grade 4 (OR 0.44, 95% CI 0.36e0.57); and in patients with aorta coverage >25 cm (OR
0.48, 95% CI 0.32e0.74). The proximal landing zone did not inﬂuence preference.
Conclusion: Specialists’ preferences for endovascular repair of degenerative dTAA vary widely, and demonstrate
clinical uncertainty, especially in octogenarians, and a reluctance to offer TEVAR to women. Aneurysm diameter
dominates treatment preferences, but patient ﬁtness and length of aortic coverage (>25 cm) also were
inﬂuential, although the landing zone distal to LSA was not.
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The incidence of degenerative descending thoracic aortic
aneurysms (dTAA) appears to be increasing, with epidemi-
ological data reporting a rise to an overall incidence of 9e
16 per 100,000 population per year.1 Recent advances in
thoracic aortic stent-graft technology and reported im-
provements in operative outcomes have resulted in an
exponential increase in the number of thoracic endovas-
cular aortic repairs (TEVARs) performed, with a particularly
marked increase in those aged 75 years and older.2 Despite
this increase in TEVAR being performed, there remains a
lack of high quality evidence concerning indications for
treatment in the elective setting. Maximum aneurysm
diameter is one of the key factors in determining rupture
risk, and is routinely used in clinicians’ decisions of whether
to recommend treatment or not. However, natural history
data and the evidence base for threshold diameters at
which dTAA repair becomes beneﬁcial remain limited to
single-centre series and registries.3,4 Perhaps unsurprisingly,
current guidelines for treatment therefore vary in recom-
mended threshold diameters, from 5.5 to 7.0 cm (Riambau
V, Böckler D, Brunkwall J, et al., submitted).4e8 The clinical
effectiveness of TEVAR also depends on other factors,
including age, sex, comorbidity, length of aortic coverage,
and the need for adjunctive surgery (debranching of supra-
aortic vessels) to extend the landing zone. All of these
factors have been reported to be risk factors for morbidity
and mortality following TEVAR for dTAA.9e13
The lack of robust evidence in this emerging ﬁeld may be
expected to lead to large variation in practice. Decisions of
whether to offer TEVAR or not in speciﬁc clinical scenarios
are likely to be inﬂuenced not only by patient and aneurysm
factors, but also by clinician factors (e.g., endovascular
experience).
A discrete choice experiment is a quantitative technique
to elicit individual preferences. Respondents complete a
survey, stating their preferences in hypothetical scenarios.
Each scenario is described by several attributes, and re-
sponses are analysed to quantify the extent to which
preferences are inﬂuenced by the attributes. Discrete
choice experiments are commonly used in health eco-
nomic research to elicit the views of patients and the
public on alternative treatment scenarios and access to
services,14e16 but the application of discrete choice ex-
periments to explore clinicians’ treatment preferences is
less common.17
The aims of this study were (1) to explore uncertainty
and variation in clinical practice in offering TEVAR or sur-
veillance to patients with dTAA; and (2) to establish the key
variables that inﬂuence specialist clinician treatment pref-
erences in patients with dTAA.Figure 1. Diagrammatic survey graph. Note. TEVAR ¼ thoracic
endovascular aortic repair.MATERIALS AND METHODS
Sample
Vascular and cardiothoracic surgeons and interventional
radiologists in independent specialist practice wererecruited face-to-face at two international vascular confer-
ences (European Society of Vascular Surgery Annual
Meeting 2012, Bologna, Italy, and the Veith Symposium
2012, New York, NY, USA) and electronically via selected
mailing lists of national (Vascular Society of Great Britain
and Canadian Society for Vascular Surgery) and interna-
tional vascular societies (European Society of Vascular Sur-
gery). Clinicians with a declared interest in thoracic aortic
surgery were identiﬁed and contacted directly.
Instruments
The diagrammatic survey comprised two sections: (1) de-
mographic information (clinician specialisation, number of
years in specialisation, country of practice, number of years
of endovascular experience, availability of TEVAR at centre);
(2) graphs of aneurysm diameter (cm) versus age (years)
(Fig. 1), administered in person (by N.R., F.H., J.T.P., or C.B.).
The questionnaire survey comprised two sections: (1) de-
mographic information (as for the diagrammatic survey); (2)
the discrete choice experiment (25 hypothetical dTAA case
scenarios). The discrete choice experiment questionnaire
survey was uploaded onto a secure web-based survey tool
to allow electronic completion (www.freeonlinesurveys.
com).
Diagrammatic survey
The diagrammatic survey asked respondents to indicate on
graphs their own areas of uncertainty about the beneﬁts of
performing TEVAR for (1) a man and (2) a woman, American
Society of Anesthesiologists (ASA) grade 3, with a fusiform
degenerative dTAA and adequate landing zone distal to the
left subclavian artery (LSA). An example response is shown
in Fig. 1.
Discrete choice experiment scenario development
The discrete choice experiment was devised using a pair-
wise choice design to reﬂect the clinical decision-making
context.18
Figure 2. Graph showing frequency of patient- and aneurysm-related attributes given in expert interviews exploring key variables
important to clinicians in determining treatment decisions for patients with descending thoracic aortic aneurysms. Note. ASA ¼ American
Society of Anesthesiologists; LSCA ¼ left subclavian artery.
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important to clinicians in determining treatment decisions
for patients with dTAA, face-to-face individual, semi-
structured interviews of ﬁve consultant vascular surgeons
at a tertiary referral regional vascular centre with a
specialist interest in thoracic aortic disease (St Mary’s
Hospital, Imperial Healthcare NHS Trust, London, UK) were
conducted by N.R. Variables were classiﬁed as patient- or
aneurysm-related, and all variables identiﬁed by four out of
ﬁve consultants were considered in the designed of discrete
choice experiment scenarios (Fig. 2).
Scenario design. Six variables were selected for inclusion
and subdivided into plausible and clinically relevant cate-
gories (Table 1). Twenty-ﬁve hypothetical scenarios were
randomly generated from the reduction of all possible
combinations of the variable levels produced by SPSS
“Orthoplan” software (IBM, Armonk, NY, USA) by fractional
factorial design, resulting in 900 potential scenarios.19 The
discrete choice experiment design was balanced in terms of
the number of times each level of a variable was repre-
sented in the scenarios.Table 1. Discrete choice experiment categories within variables studie
Variable Levels
Age (y) 60e65 >65
Sex M F
ASA grade 2 3
Aneurysm diameter (cm) 4.5e5.0 >5.0
Adequate landing zone distal to LSA Yes No
Length of aortic coverage (cm) 10e20 >20
Note. ASA ¼ American Society of Anesthesiologists; LSA ¼ left subclaDiscrete choice experiment questionnaire survey
Clinicians were asked to indicate their treatment preference
for each of the 25 hypothetical scenarios (presented to
respondents in random order) based on the combinations
of variables presented (see example scenario in Fig. 3). Two
treatment preferences were offered: TEVAR or surveillance.
Open surgical repair was excluded from the exercise. In-
vitations were e-mailed once to 86 members of the Euro-
pean Society of Vascular Surgery and 152 members of the
Canadian Society of Vascular Surgery. The discrete choice
experiment took around 30 minutes to complete.
Statistical analyses
Survey responses were summarised with descriptive sta-
tistics. Responses to the discrete choice experiment sce-
narios were analysed to investigate the impact of patient
and participant attributes on the management preferences
of participants. The odds for preferring TEVAR compared
with surveillance (odds ratios [ORs]) were estimated by
ﬁtting uni- and multivariable random effects logit models
(i.e., logistic regression taking into account the clustering ofd.
e70 >70e75 >75e80 >80e85
4
e5.5 >5.5e6.0 >6.0e6.5 >6.5e7.0
e25 >25
vian artery; M ¼ male; F ¼ female.
Figure 3. Discrete choice experiment sample scenario. Note.
ASA ¼ American Society of Anesthesiologists; TEVAR ¼ thoracic
endovascular aortic repair.
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within variables were ﬁtted with dummy variables, avoiding
any assumption of a linear relationship. Multivariable
models were ﬁtted, starting with all variables and removing
those that did not improve the goodness of ﬁt of the overall
model (Wald test, p > .05). In order to preserve degrees of
freedom for multicategory variables, categories were com-
bined with the reference category when ORs did not differ
from the reference category. A best-ﬁtting model for patient
attributes was estimated ﬁrst. A subsequent model
attempted to add respondents’ attributes.RESULTS
First, uncertainty about the beneﬁt of TEVAR for dTAA by
age, diameter, and sex was assessed, with 50 specialists
completing a pilot diagrammatic survey (Septembere
November 2012). Clinicians were approached directly byTable 2. Demographics of responders to diagrammatic survey.
n %
Speciality Vascular Surgery 43 86
Interventional Radiology 5 10
Vascular Surgery and
Interventional Radiology
1 2
Cardiovascular Surgery 1 2
Country of practice UK 19 38
Europe (outside of UK) 23 46
USA 1 2
Other 7 14
Years in specialist
practice
0e5 10 20
>5e10 16 32
>10e20 14 28
>20 10 20
Years in endovascular
practice
0e5 11 22
>5e10 28 56
>10e20 8 16
>20 3 6
TEVAR available at
centre?
Yes 49 98
No 1 2
Note. TEVAR ¼ thoracic aortic aneurysms.the authors, and the response rate was >90%. The majority
were specialists in vascular surgery, practising in the UK or
Europe, with 5e10 years of specialist and endovascular
experience, and offering TEVAR at their centre (Table 2).
The responses showed a wide range of practice and
considerable clinical uncertainty (Fig. 4). Specialists varied in
the threshold diameter at which they would offer TEVAR
over surveillance: median 6.0 cm for men (interquartile
range [IQR] 5.5e6.0 cm, range 4.0e6.5 cm) and 5.5 cm for
women (IQR 5.0e5.9 cm, range 4.0e6.5 cm). Uncertainty in
the threshold for offering TEVAR was greatest for patients
aged 80e85 years (up to 47% of respondents were “un-
sure”), and this increased with increasing aneurysm diam-
eter (e.g., for an 80-year-old man 7% were unsure at 5.5 cm,
16% were unsure at 6.0 cm, and 33% were unsure at
7.0 cm). The uncertainty was greater for smaller diameters
for women (e.g., for an 80-year-old woman 10% were un-
sure at 5.5 cm and 20% were unsure at 6.0 cm).
For the discrete choice experiment, the web-based
response rate was low (30% from Europeans and 19%
from Canadians). Overall, 71 specialists completed the
discrete choice experiment. The demographics of the re-
spondents are summarised in Table 3. The majority were
specialists in vascular surgery, from Canada, with 10e20
years of specialist practice and endovascular experience,
and working in hospitals that carried out TEVAR.
The 71 respondents answered 1,775 (71  25) scenarios;
the results are summarised in Table 4. In 959 (54%) sce-
narios the responders preferred surveillance and 816 (46%)
preferred TEVAR. Overall, there was a lack of consensus in
clinicians’ preferences: in 15 out of the 25 scenarios, fewer
than 75% of responses were for one preference. For
example, in scenario 13, which described a man aged be-
tween 65 and 70 years, of ASA grade 2, with a maximum
aneurysm diameter of between 5.5 and 6.0 cm, with no
landing zone distal to the LSA, and requiring 10e20 cm of
length of aortic coverage, 58% of respondents preferred
surveillance, while 42% preferred TEVAR.
Clinicians did demonstrate a clear consensus in some
scenarios. For example, 99% of respondents preferred sur-
veillance in scenario four, which described a man aged
between 80 and 85 years, of ASA grade 3, with a maximum
aneurysm diameter between 4.5 and 5.0 cm, with no
landing zone distal to the LSA, and requiring 10e20 cm of
length of aortic coverage. All respondents preferred TEVAR
in scenario 14, which described a man aged between 65 and
70 years, of ASA grade 2, with a maximum aneurysm
diameter of between 6.5 and 7.0 cm with an adequate
landing zone distal to the LSA, and requiring between 20
and 25 cm in length of aortic coverage.
In univariable analyses, some categories of all variables,
except for adequacy of landing zone distal to LSA, were
independently associated with clinician preference
(Table 4). Preference for surveillance was associated
(OR < 1.00) with increasing age, female sex, increasing ASA
grade, and increasing length of aortic coverage. Preference
for TEVAR was strongly associated with increasing aneurysm
diameter.
Figure 4. Graphs showing results of diagrammatic survey with percentage of respondents indicating thoracic endovascular aortic repair
beneﬁt (no, unsure, or yes) according to aneurysm diameter (a) for a man with a fusiform degenerative descending thoracic aortic
aneurysm (dTAA) with an adequate landing zone distal to the left subclavian artery (LSA), American Society of Anesthesiologists (ASA)
grade 3, and (b) for a woman with a fusiform degenerative dTAA with an adequate landing zone distal to LSA, ASA grade 3.
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Table 3. Demographics of responders to discrete choice
experiment questionnaire.
n %
Speciality Vascular Surgery 63 88.7
Interventional Radiology 5 7.0
Vascular Surgery and
Interventional Radiology
2 2.8
Cardiovascular Surgery 1 1.4
Country of practice UK 16 22.5
Rest of Europe 21 29.6
USA and Mexico 5 7.0
Canada 29 40.8
Years in specialist
practice
0e5 11 15.5
>5e10 19 26.8
>10e20 26 36.6
>20 15 21.1
Years in endovascular
practice
0e5 12 16.9
>5e10 25 35.2
>10e20 42 59.2
>20 2 2.8
TEVAR available at
centre?
Yes 67 94.4
No 4 5.6
Note. TEVAR ¼ thoracic aortic aneurysms.
Table 4. Results by scenario.a
Case Age (y) Sex ASA
grade
Aneurysm
diameter (cm)
Adequate la
zone distal
1 >75e80 F 2 4.5e5.0 Yes
2 60e65 M 4 >5.5e6.0 Yes
3 >70e75 F 2 >6.0e6.5 Yes
4 >80e85 M 3 4.5e5.0 No
5 >75e80 M 3 >6.0e6.5 No
6 >75e80 M 3 >5.0e5.5 Yes
7 >70e75 M 2 >5.0e5.5 Yes
8 >80e85 M 2 >6.5e7.0 Yes
9 >70e75 M 3 >6.5e7.0 No
10 >65e70 F 4 >5.0e5.5 No
11 >65e70 F 3 4.5e5.0 Yes
12 >65e70 M 3 >6.0e6.5 Yes
13 >65e70 M 2 >5.5e6.0 No
14 >65e70 M 2 >6.5e7.0 Yes
15 >80e85 F 2 >5.0e5.5 No
16 >75e80 M 2 >5.5e6.0 No
17 60e64 M 3 >5.0e5.5 Yes
18 >70e75 M 4 4.5e5.0 No
19 60e65 F 3 >6.5e7.0 No
20 >80e85 M 4 >6.0e6.5 Yes
21 >70e75 F 3 >5.5e6.0 Yes
22 60e65 M 2 4.5e5.0 Yes
23 60e65 F 2 >6.0e6.5 No
24 >75e80 F 4 >6.5e7.0 Yes
25 >80e85 F 3 >5.5e6.0 Yes
Note. ASA ¼ American Society of Anesthesiologists; LSA ¼ left subcla
a Summary of raw data.
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multiple logistic regression analyses, after inspecting the
models with all categories, in order to maximise the pre-
cision of estimates. These analyses, which adjusted the as-
sociation of TEVAR preference with each variable for
associations with all other variables, showed that increasing
aneurysm diameter still had the strongest inﬂuence on
treatment decisions: >5.5e6.0 cm, adjusted OR ¼ 15.8
(95% conﬁdence interval [CI] 9.83e25.4); >6.0e6.5 cm,
OR ¼ 393 (95% CI 202.00e766.00); >6.5e7.0 cm,
OR ¼ 1,829 (95% CI ¼ 400.00e4,181.00). Clinicians were
much less likely to select TEVAR in older patients compared
with patients aged 60e75 years: >75e80 years, OR ¼ 0.32
(95% CI 0.21e0.49); >80e85 years, OR ¼ 0.18 (95%
CI ¼ 0.11e0.28). Clinicians were only about half as likely to
select TEVAR for women compared with men (OR 0.52, 95%
CI 0.37e0.74). A few selected TEVAR for patients of ASA
grade 4, but this was much less likely than for patients with
ASA grades 2 or 3 (OR 0.44, 95% CI 0.36e0.57). There also
was reduced enthusiasm for offering TEVAR where the
required length of aorta coverage was >25 cm compared
with patients requiring 10e25 cm only (OR 0.48, 95% CI
0.32e0.74).
Univariable analyses of respondent attributes did not
yield any compelling results, largely because the number of
respondents limited the power of the analyses. The data
suggested that specialists in Canada were less likely to offer
TEVAR than those practising elsewhere (Table 5). Thending
to LSA
Length of aortic
coverage (cm)
Preference for
surveillance (%)
Preference for
TEVAR (%)
>20e25 91.5 8.5
>20e25 62.0 38.0
10e20 2.8 97.2
10e20 98.6 1.4
10e20 21.1 78.9
>20e25 88.7 11.3
>25 88.6 11.4
10e20 2.9 97.1
>20e25 4.3 95.7
10e20 94.4 5.6
>25 95.8 4.2
>20e25 8.5 91.5
10e20 57.7 42.3
>20e25 0 100.0
>20e25 93.0 7.0
>25 67.6 32.4
10e20 85.9 14.1
>20e25 98.6 1.4
>25 4.2 95.8
>25 59.2 40.8
10e20 38.0 62.0
10e20 95.8 4.2
>20e25 5.6 94.4
10e20 18.3 81.7
>20e25 69.0 31.0
vian artery; TEVAR ¼ thoracic endovascular aortic repair.
Table 5. Inﬂuence of each discrete choice experiment variable over treatment preference.
Variable Univariable OR
(95% CI)
Multivariable OR
(95% CI)
Patient characteristics only
Clinical scenario attributes
Agea 60e65 1.00 (reference)
>65e70 0.96 (0.76e1.21)
>70e75 1.16 (0.92e1.47) 1.00 (reference 60e75 y)
>75e80 0.74 (0.58e0.98) 0.32 (0.21e0.49)
>80e85 0.54 (0.42e0.68) 0.18 (0.11e0.28)
Sex M 1.00 (reference) 1.00 (reference)
F 0.79 (0.68e0.92) 0.52 (0.37e0.74)
ASA gradeb 2 1.00 (reference)
3 0.94 (0.79e1.12) 1.00 (reference ASA grade 2 or 3)
4 0.49 (0.39e0.63) 0.44 (0.36e0.57)
Aneurysm diameter (cm)c 4.5e5.0 1.00 (reference)
>5.0e5.5 1.21 (0.64e2.26) 1.00 (reference, diameter 4.5e5.5 cms)
>5.5e6.0 15.8 (8.76e28.7) 15.8 (9.83e25.4)
>6.0e6.5 188 (95.6e372) 393 (202e766)
>6.5e7.0 972 (434e2180) 1829 (400e4,181)
Adequate landing zone distal to LSA No 1.00 (reference) Not included in model (not predictive)
Yes 0.91 (0.78e1.06)
Length aortic coverage (cm)d 10e20 1.00 (reference)
>20e25 0.93 (0.7e1.11) 1.00 (reference 10e25 cm)
>25 0.59 (0.46e0.74) 0.48 (0.32e0.74)
Respondent attributes
Speciality Vascular 1.00 (reference)
IR 0.78 (0.46e1.34)
Vascular and IR 0.78 (0.33e1.82)
CTS 0.46 (0.13e1.59)
Number years in specialisation 0e5 1.00 (reference)
>5e10 0.89 (0.68e1.17)
>10e15 0.81 (0.56e1.17)
>15e20 0.85 (0.64e1.14)
>20 0.75 (0.55e1.02)
Number years endovascular experience 0e5 1.00 (reference)
>5e10 0.95 (0.75e1.20)
>10e15 0.74 (0.57e0.97)
>15 0.89 (0.65e1.21)
Country of practice UK 1.00 (reference)
Canada 0.73 (0.59e0.90)
USA and Mexico 1.55 (0.93e2.58)
Rest of Europe 1.20 (0.94e1.53)
TEVAR at centre No 1.00 (reference)
Yes 0.85 (0.74e0.98)
Note. OR ¼ odds ratio; CI ¼ conﬁdence interval; ASA ¼ American Society of Anesthesiologists; LSA ¼ left subclavian artery;
TEVAR ¼ thoracic endovascular aortic repairs; M ¼ male; F ¼ female; IR ¼ interventional radiology; CTS ¼ cardiothoracic surgery.
a The three youngest categories were combined in multivariable models.
b ASA classes 2 and 3 were combined in multivariable models.
c The two smallest diameter categories were combined in multivariable models.
d The two shortest aortic length coverage categories were combined in multivariable models.
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20 N. Rudarakanchana et al.suggested trends for clinicians to prefer surveillance over
TEVAR with increasing years of specialisation and endo-
vascular practice did not achieve statistical signiﬁcance. We
attempted to ﬁt multivariable models, adding respondent
attributes to discrete choice experiment variables, but
adding respondent attributes did not improve the ﬁt of the
model, possibly because the study had relatively low power
for respondent-level attributes or because of strong corre-
lations between respondent attributes.DISCUSSION
Despite recent publications of national and international
guidelines for the management of patients with dTAA, there
remains a lack of contemporary evidence to underpin such
guidelines. Our results suggest wide variation in practice, as
well as uncertainty amongst vascular specialists concerning
the management of degenerative dTAA in those older than
75 years, and especially in octogenarians. Uncertainty in
this age group is of great clinical relevance because it is
probably the age group in which both the incidence of dTAA
and an increase in TEVAR procedures is highest.2 TEVAR was
only half as likely to be selected for women compared with
men. Age, sex, and ASA grade all inﬂuenced treatment
preferences, although aneurysm diameter had the strongest
inﬂuence.
There is some evidence to support the tendency for cli-
nicians to prefer surveillance with increasing patient age. In
the MOTHER database of 1,010 TEVAR patients (an amal-
gamation of device-speciﬁc Medtronic registries, which in-
cludes TEVARs performed for a range of pathologies),
increasing age is an independent predictor of 30-day mor-
tality, with an OR of 1.05 per additional year.4 In single-
centre series of TEVAR, each of around 200 patients, aged
>70 years and >80 years are risk factors in models pre-
dicting longer term mortality, with hazard ratios of 5.0e
6.0.10,20 However, increasing age may not be signiﬁcantly
associated with inpatient mortality.21 The relationship be-
tween age and re-intervention is not clear: Alsac et al.21
report an increased risk in patients aged >80 years, while
Lee et al.22 found a higher risk in younger patients, owing,
perhaps, to progressive aortic dilatation or a higher preva-
lence of genetic disease.
While women have higher mortality rates than men af-
ter endovascular treatment of abdominal aortic aneu-
rysms, similar results for TEVAR have not been
demonstrated. Clinicians may be generalising from this
knowledge to dTAA, but there is little evidence seen in our
results to justify the ﬁnding of reluctance to use TEVAR in
women. Women are reported to have higher rates of
vascular access-related complications, but this does not
appear to translate into greater postoperative mortal-
ity,24,25 and women may even have more favourable out-
comes at 1-year follow-up, with less proximal endoleak or
aneurysm growth,25 although these data are not adjusted
for aneurysm diameter.
In contrast, the preference for surveillance in patients
with ASA grade 4 has a ﬁrmer evidence base, with manyreports conﬁrming a signiﬁcant association between co-
morbidity and postoperative mortality.4,9,10,20,21,24 In the
MOTHER registry, ASA grade was an independent predictor
of 30-day mortality, with an OR of 2.34 per increase in
grade.4
The evidence for treatment threshold diameters for dTAA
repair is derived largely from a long-running observational
study from the USA.3 This study, beginning in the 1980s,
shows a hinge-point of 7 cm, after which the risk of rupture
escalates sharply to 28%. However, only a third of the pa-
tients in the US study had dTAA (most had ascending aortic
disease); the majority were not treated with statins and the
method of diameter measurement was not standardised.3
Establishing an evidence-based treatment threshold diam-
eter would require knowledge of the natural history of
dTAA in the context of contemporary medical therapy
together with long-term TEVAR outcomes; there is currently
a paucity of high-level evidence in both areas. The very
marked preference for TEVAR in younger men, even at di-
ameters of 5.5 cm, is therefore surprising.
Aortic anatomy appears to have far less inﬂuence on
treatment decision making, with LSA involvement not
inﬂuencing treatment decisions, and a preference for sur-
veillance only if >25 cm aortic coverage is required. Pub-
lished data do not support these preferences. In a study of
nearly 850 patients, Chung et al.9 reported an OR of 2.17 for
stroke following LSA coverage. The EUROSTAR registry of
606 patients showed an OR of 3.9 for spinal cord ischaemia
following LSA coverage without revascularisation, and a
combined stroke or paraplegia rate of 8% in patients with
LSA coverage compared with 0% in patients who underwent
prophylactic revascularisation.13 Several studies conﬁrm
that the risk of spinal cord injury increases with longer
length of aortic coverage,11e13 even with coverage of
<25 cm and the use of adjunctive measures (e.g., spinal
drain).Limitations
Although the response rate to the discrete choice experi-
ment survey was high when administered in person, there
was a low response rate to the web-based survey (30% of
the European and 19% of the Canadian surgeons contacted
via e-mail). This may be a reﬂection of the length of the
survey and respondent fatigue. Repeat e-mail requests may
have improved the response rates. Given the low response
rate, respondents may not be representative of specialists
in the participating countries.23 In addition, 85% of re-
spondents to the discrete choice experiment were vascular
surgeons, and 98% worked in units that offer TEVAR; as
such, the results of this study are biased towards prefer-
ences of this clinician demographic. Discrete choice exper-
iments assume that all attributes are independent, which is
to say that the inﬂuence on preference of one attribute
does not vary according the changes in a different attri-
bute.16 However, in this study, it is probable, for example,
that age and ASA grade are, to a degree, interdependent,
with a greater age being associated with a higher ASA
European Journal of Vascular and Endovascular Surgery Volume 48 Issue 1 p. 13e22 July/2014 21grade. Importantly, this study does not purport to give a
description of actual clinical practice in this area; in reality,
treatment decisions may be inﬂuenced by a number of
other factors that we were not able to include in the
experiment owing to sample size and power considerations,
not least patient preference and other anatomical factors,
for example the presence of thrombus in the arch. We were
also not able to include open surgical repair as a treatment
option owing to pragmatic considerations of sample size
and statistical power. In addition, the relatively small
number of respondents prevented us from reliably esti-
mating how clinician attributes may inﬂuence preference
for TEVAR.Conclusions
This study has uncovered strong ageism and sexism in
preferences (elicited in the context of the discrete choice
experiment) regarding when to treat descending thoracic
aortic aneurysms with TEVAR and wide variation in pref-
erences across the diameter categories considered. The
spread of responses given in both surveys probably reﬂects
the large evidence gap in this clinical question and high-
lights the need for a randomised controlled trial to examine
the relative beneﬁts of surveillance or TEVAR in patients
with small dTAA.FUNDING
This research was funded by the National Institute for
Health Research (NIHR) Biomedical Research Centre based
at Imperial College Healthcare National Health Service
(NHS) Trust and Imperial College London. The views
expressed are those of the authors and not necessarily
those of the NHS, NIHR, or the Department of Health.CONFLICT OF INTEREST
None.
ACKNOWLEDGEMENTS
We would like to thank Professor Thomas Forbes and Mr
Simon Parvin for their help in contacting members of the
Canadian and European Vascular Society members,
respectively.REFERENCES
1 Olsson C, Thelin S, Ståhle E, Ekbom A, Granath F. Thoracic aortic
aneurysm and dissection: increasing prevalence and improved
outcomes reported in a nationwide population-based study of
more than 14,000 cases from 1987 to 2002. Circulation
2006;114(24):2611e8.
2 von Allmen RS, Anjum A, Powell JT. Incidence of descending
aortic pathology and evaluation of the impact of thoracic
endovascular aortic repair: a population-based study in En-
gland and Wales from 1999 to 2010. Eur J Vasc Endovasc Surg
2013;45(2):154e9.
3 Coady MA, Rizzo JA, Hammond GL, Kopf GS, Elefteriades JA.
Surgical intervention criteria for thoracic aortic aneurysms: astudy of growth rates and complications. Ann Thorac Surg
1999;67:1922e6.
4 Patterson B, Holt P, Nienaber C, Cambria R, Fairman R,
Thompson M. Aortic pathology determines midterm outcome
after endovascular repair of the thoracic aorta: report from the
Medtronic thoracic endovascular registry (MOTHER) database.
Circulation 2013;127(1):24e32.
5 Elefteriades JA. Natural history of thoracic aortic aneurysms:
indications for surgery, and surgical versus nonsurgical risks.
Ann Thorac Surg 2002;74(5):S1877e80.
6 Svensson LG, Kouchoukos NT, Miller DC, Bavaria JE, Coselli JS,
Curi MA, et al. Society of Thoracic Surgeons Endovascular
Surgery Task Force. Expert consensus document on the treat-
ment of descending thoracic aortic disease using endovascular
stent-grafts. Ann Thorac Surg 2008;85(1 Suppl.):S1e41.
7 Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF,
Casey Jr DE, et al. American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guidelines.
American Association for Thoracic Surgery. American College of
Radiology. American Stroke Association. Society of Cardiovas-
cular Anesthesiologists. Society for Cardiovascular Angiography
and Interventions. Society of Interventional Radiology. Society
of Thoracic Surgeons. Society for Vascular Medicine. 2010
ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines
for the diagnosis and management of patients with Thoracic
Aortic Disease: a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice
Guidelines, American Association for Thoracic Surgery, Amer-
ican College of Radiology, American Stroke Association, Society
of Cardiovascular Anesthesiologists, Society for Cardiovascular
Angiography and Interventions, Society of Interventional
Radiology, Society of Thoracic Surgeons, and Society for
Vascular Medicine. Circulation 2010;121(13):e266e369.
8 Grabenwöger M, Alfonso F, Bachet J, Bonser R, Czerny M,
Eggebrecht H, et al. European Association for Cardio-Thoracic
Surgery (EACTS). European Society of Cardiology (ESC). Euro-
pean Association of Percutaneous Cardiovascular Interventions
(EAPCI). Thoracic Endovascular Aortic Repair (TEVAR) for the
treatment of aortic diseases: a position statement from the
European Association for Cardio-Thoracic Surgery (EACTS) and
the European Society of Cardiology (ESC), in collaboration with
the European Association of Percutaneous Cardiovascular In-
terventions (EAPCI). Eur J Cardiothorac Surg 2012;42(1):17e24.
9 Chung J, Corriere MA, Veeraswamy RK, Kasirajan K, Milner R,
Dodson TF, et al. Risk factors for late mortality after endo-
vascular repair of the thoracic aorta. J Vasc Surg 2010;52(3):
549e54.
10 Scali ST, Chang CK, Feezor RJ, Hess Jr PJ, Beaver TM, Martin TD,
et al. Preoperative prediction of mortality within 1 year after
elective thoracic endovascular aortic aneurysm repair. J Vasc
Surg 2012;56(5):1266e72.
11 Amabile P, Grisoli D, Giorgi R, Bartoli JM, Piquet P. Incidence
and determinants of spinal cord ischaemia in stent-graft repair
of the thoracic aorta. Eur J Vasc Endovasc Surg 2008;35:
455e61.
12 Drinkwater SL, Goebells A, Haydar A, Bourke P, Brown L,
Hamady M, et al. Regional Vascular Unit, St Mary’s Hospital,
Imperial College NHS Trust. The incidence of spinal cord
ischaemia following thoracic and thoracoabdominal aortic
endovascular intervention. Eur J Vasc Endovasc Surg
2010;40(6):729e35.
13 Buth J, Harris PL, Hobo R, van Eps R, Cuypers P, Duijm L, et al.
Neurologic complications associated with endovascular repair
22 N. Rudarakanchana et al.of thoracic aortic pathology: incidence and risk factors. A study
from the European Collaborators on Stent/Graft Techniques for
Aortic Aneurysm Repair (EUROSTAR) registry. J Vasc Surg
2007;46(6):1103e10.
14 Coast J, Salisbury C, de Berker D, Noble A, Horrocks S, Peters TJ,
et al. Preferences for aspects of a dermatology consultation. Br
J Dermatol 2006;155:387e92.
15 Gerard K, Lattimer V. Preferences of patients for emergency
services available during usual GP surgery hours: a discrete
choice experiment. Fam Pract 2005;22:28e36.
16 Caldron LJM,Wlater SJ, Ratcliffe J, Reed MWR.What inﬂuences
clinicians’ operative preferences for women with breast can-
cer? An application of the discrete choice experiment. Eur J
Cancer 2007;43(11):1662e9.
17 Ryan M, Gerard K. Using discrete choice experiments to value
health care programmes: current practice and future research
reﬂections. Appl Health Econ Health Policy 2003;2(1):55e64.
18 Bradley M. Users manual for the speed version 2.1 stated
preference editor and designer. Hague: Hague Consulting
Group; 1991.
19 Lee WA, Daniels MJ, Beaver TM, Klodell CT, Raghinaru DE,
Hess Jr PJ. Late outcomes of a single-center experience of 400consecutive thoracic endovascular aortic repairs. Circulation
2011;123(25):2938e45.
20 Wiedemann D, Mahr S, Vadehra A, Schoder M, Funovics M,
Löwe C, et al.Thoracic endovascular aortic repair in 300 patients:
long-term results. Ann Thorac Surg 2013;95(5):1577e83.
21 Alsac JM, Khantalin I, Julia P, Achouh P, Farahmand P, Capdevila C,
et al. The signiﬁcance of endoleaks in thoracic endovascular
aneurysm repair. Ann Vasc Surg 2011;25(3):345e51.
22 Lee CJ, Rodriguez HE, Kibbe MR, Malaisrie SC, Eskandari MK.
Secondary interventions after elective thoracic endovascular
aortic repair for degenerative aneurysms. J Vasc Surg
2013;57(5):1269e74.
23 Dillavou ED, Makaroun MS. Predictors of morbidity and mor-
tality with endovascular and open thoracic aneurysm repair.
J Vasc Surg 2008;48(5):1114e9.
24 Jackson BM, Woo EY, Bavaria JE, Fairman RM. Gender analysis
of the pivotal results of the Medtronic Talent Thoracic Stent
Graft System (VALOR) trial. J Vasc Surg 2011;54(2):358e63.
25 Jovin IS, Duggal M, Ebisu K, Paek H, Oprea AD, Tranquilli M,
et al. Comparison of the effect on long-term outcomes in pa-
tients with thoracic aortic aneurysms of taking versus not
taking a statin drug. Am J Cardiol 2012;109(7):1050e4.
